3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Prostatic Neoplasms
25
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma
15
Burkitt Lymphoma
11
Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Follicular
7
Lymphoma, B-Cell
7
Hodgkin Disease
6
Lymphoma, Non-Hodgkin
5
Recurrence
3
Prostatic Neoplasms, Castration-Resistant
3
Leukemia
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Melanoma
2
Lymphoproliferative Disorders
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, AIDS-Related
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Biphenotypic, Acute
2
Immunoblastic Lymphadenopathy
2
Vasculitis, Central Nervous System
1
Urogenital Neoplasms
1
Stiff-Person Syndrome
1
Stage II Prostate Adenocarcinoma
1
Skin Neoplasms
1
Rasmussen subacute encephalitis
1
Prostate Cancer, Hereditary, 7
1
Interventions
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
Bendamustine Hydrochloride
2
sepantronium
1
acalabrutinib
1
Vincristine
1
Rituximab
1
Prednisone
1
Doxorubicin
1
Brentuximab Vedotin
1
Bone Marrow Transplantation
1
ARQ531
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphatic Diseases
×
Prednisone
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled